| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
XL177A targets USP7, a deubiquitinating enzyme that plays a crucial role in regulating protein degradation and maintaining cellular protein homeostasis. It acts as a potent and selective irreversible USP7 inhibitor with an IC50 of 0.34 nM. XL177A elicits cancer cell killing through a p53-dependent mechanism.
|
|---|---|
| ln Vitro |
XL177A is a strong conjugator of USP7 that stabilizes p53 in cells. The primary mechanism by which XL177A reduces insulin growth is through p53 oscillation. In the human proteome and DUBome, XL177A identifies the catalytic cysteine C223 of USP7 [1]. In MCF7 cells, XL177A (1 μM) causes total G1 arrest after 24 hours [1]. Results of inducing HDM2 breakdown in less than two seconds: elevated amounts of p21 protein, but not of p53 or p21 [1]. MDM2 protein levels were in line with DMSO benchmarks.
In vitro, XL177A is a highly potent and selective irreversible USP7 inhibitor with an IC50 of 0.34 nM. The primary mechanism by which XL177A reduces cancer cell growth is through p53 stabilization and oscillation. The compound shows selectivity across the human proteome. |
| ln Vivo |
In vivo activity data for XL177A are not extensively detailed in the available sources. The compound is a research tool for studying USP7 function and p53-mediated cancer cell killing. Specific in vivo efficacy data in animal models have not been reported.
|
| Enzyme Assay |
The in vitro enzyme assay for XL177A involves measuring the inhibition of USP7 deubiquitinating activity. Recombinant USP7 is incubated with a ubiquitinated substrate in the presence of varying compound concentrations. The IC50 value (0.34 nM) is determined by quantifying the reduction in substrate deubiquitination using fluorescence-based or ELISA-based assays.
|
| Cell Assay |
Cellular assays are performed using cancer cell lines (e.g., MCF7). Cells are treated with XL177A at varying concentrations. p53 stabilization is assessed by Western blotting. Cell viability and apoptosis are measured using standard assays.
|
| Animal Protocol |
In vivo animal studies for XL177A are not detailed in the available sources. The compound is a research tool for studying USP7 function in cancer. Specific animal models, dosing regimens, and efficacy data have not been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for XL177A are not available in the provided sources. The compound has a molecular weight of 861.47 g/mol. It is soluble in DMSO at 50 mg/mL (58.04 mM). Powder formulations should be stored at -20°C. Specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicity data for XL177A are not reported in the available sources. As a research compound, it is not intended for therapeutic use. Specific toxicological profiles have not been characterized.
|
| References | |
| Additional Infomation |
XL177A is a research compound for studying USP7 function in cancer. It is a highly potent and selective irreversible USP7 inhibitor that elicits cancer cell killing through a p53-dependent mechanism. The compound is available from commercial suppliers for research use only.
|
| Molecular Formula |
C48H57CLN8O5
|
|---|---|
| Molecular Weight |
861.4698
|
| Exact Mass |
860.41
|
| Elemental Analysis |
C, 66.92; H, 6.67; Cl, 4.11; N, 13.01; O, 9.29
|
| CAS # |
2417089-74-6
|
| Related CAS # |
2417089-73-5 2417089-74-6 (S-isomer);2417089-75-7 (R-isomer);
|
| PubChem CID |
153002269
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
62
|
| Complexity |
1560
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CN1CCN(CC1)CCC(=O)NC2=CC3=C(C=C2)C(=O)N(C=N3)CC4(CCN(CC4)C(=O)[C@@H](CCCNC(=O)C5=CC6=C(C=C5)C(=C7CCCCC7=N6)Cl)CC8=CC=CC=C8)O
|
| InChi Key |
UYJWYMWIVMCGQZ-DHUJRADRSA-N
|
| InChi Code |
InChI=1S/C48H57ClN8O5/c1-54-24-26-55(27-25-54)21-17-43(58)52-36-14-16-39-41(30-36)51-32-57(47(39)61)31-48(62)18-22-56(23-19-48)46(60)35(28-33-8-3-2-4-9-33)10-7-20-50-45(59)34-13-15-38-42(29-34)53-40-12-6-5-11-37(40)44(38)49/h2-4,8-9,13-16,29-30,32,35,62H,5-7,10-12,17-28,31H2,1H3,(H,50,59)(H,52,58)/t35-/m0/s1
|
| Chemical Name |
N-[(4S)-4-benzyl-5-[4-hydroxy-4-[[7-[3-(4-methylpiperazin-1-yl)propanoylamino]-4-oxoquinazolin-3-yl]methyl]piperidin-1-yl]-5-oxopentyl]-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
|
| Synonyms |
XL177A; XL-177A; XL 177A; XL177; XL-177; XL 177;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~29.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1608 mL | 5.8040 mL | 11.6081 mL | |
| 5 mM | 0.2322 mL | 1.1608 mL | 2.3216 mL | |
| 10 mM | 0.1161 mL | 0.5804 mL | 1.1608 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
